Abstract
Purpose
To evaluate effectiveness and safety of mycophenolate mofetil (MMF) monotherapy in paediatric autoimmune uveitis.
Methods
We reviewed medical records of patients, 18 years of age or younger, with autoimmune uveitis treated with MMF at our practice from 2005 to 2009. The dose and duration of MMF therapy, inflammation status, visual acuity, previous immunomodulatory therapies, and adverse effects were recorded. In addition, the following subgroups were defined: (1) Durable Disease Control: patients whose uveitis remained quiescent for at least 2 years on MMF monotherapy, with no more than two flare-ups successfully treated with an increase in MMF dosage and/or a short course (<1 month) of corticosteroids; (2) Short-term Inflammation Control: patients whose uveitis remained quiescent for less than 2 years, with no more than one flare-up successfully treated with an increase in MMF dosage and/or a short course of corticosteroids, or who initially achieved inflammation control but discontinued MMF because of significant adverse effects.
Results
A total of 38 out of 52 patients (73.1%) obtained inflammation control following 2 months of MMF monotherapy, achieving ≤0.5+ grading in anterior chamber cell/flare and vitreous haze. In the cross-sectional analysis, 25 patients (48.1%) met the criteria for Durable Disease Control, and 13 others (25.0%) qualified for Short-term Inflammation Control. Visual acuity remained stable or improved in 94.2% of the study population. Six patients (11.5%) discontinued MMF because of significant adverse effects, the most common of which was gastrointestinal disturbances.
Conclusion
MMF monotherapy appears to be an effective and safe treatment in paediatric autoimmune uveitis.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Boer J, Wulffraat N, Rothova A . Visual loss in uveitis of childhood. Br J Ophthalmol 2003; 87: 879–884.
Rosenberg KD, Feuer WJ, Davis JL . Ocular complications of paediatric uveitis. Ophthalmology 2004; 111: 2299–2306.
Holland GN, Stiehm ER . Special considerations in the evaluation and management of uveitis in children. Am J Ophthalmol 2003; 135: 867–878.
Holz FG, Krastel H, Breitbart A, Schwarz-Eywill M, Pezzutto A, Völcker HE . Low-dose methotrexate treatment in noninfectious uveitis resistant to corticosteroids. Ger J Ophthalmol 1992; 1: 142–144.
Dev S, McCallum RM, Jaffe GJ . Methotrexate treatment for sarcoid-associated panuveitis. Ophthalmology 1999; 106: 111–118.
Kremer JM . Methotrexate and emerging therapies. Clin Exp Rheumatol 1999; 17 (6 Suppl 18): S43–S46.
Wallace CA . The use of methotrexate in childhood rheumatic diseases. Arthritis Rheum 1998; 41: 381–391.
Foeldvari I, Wierk A . Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis. J Rheumatol 2005; 32: 362–365.
Heiligenhaus A, Mingels A, Heinz C, Ganser G . Methotrexate for uveitis associated with juvenile idiopathic arthritis: value and requirement for additional anti-inflammatory medication. Eur J Ophthalmol 2007; 17: 743–748.
Kingdon EJ, McLean AG, Psimenou E, Davenport A, Powis SH, Sweny P et al. The safety and efficacy of MMF in lupus nephritis: a pilot study. Lupus 2001; 10: 606–611.
Sollinger HW, US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225–232.
European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995; 345: 1321–1325.
Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61: 1029–1037.
Smith JM, Nemeth TL, McDonald RA . Current immunosuppressive agents in paediatric renal transplantation: efficacy, side-effects and utilization. Pediatr Transplant 2004; 8: 445–453.
Dipchand AI, Benson L, McCrindle BW, Coles J, West L . Mycophenolate mofetil in paediatric heart transplant recipients: a single-center experience. Pediatr Transplant 2001; 5: 112–118.
Van Mourik ID, Kelly DA . Immunosuppressive drugs in paediatric liver transplantation. Paediatr Drugs 2001; 3: 43–60.
Filler G, Hansen M, LeBlanc C, Lepage N, Franke D, Mai I et al. Pharmacokinetics of mycophenolate mofetil for autoimmune disease in children. Pediatr Nephrol 2003; 18: 445–449.
Rao VK, Dugan F, Dale JK, Davis J, Tretler J, Hurley JK et al. Use of mycophenolate mofetil for chronic refractory immune cytopenias in children with autoimmune lymphoproliferative syndrome. Br J Haematol 2005; 129: 534–538.
Moudgil A, Bagga A, Jordan SC . Mycophenolate mofetil therapy in frequently relapsing steroid-dependent and steroid-resistant nephrotic syndrome of childhood: current status and future directions. Pediatr Nephrol 2005; 20: 1376–1381.
Novak I, Frank R, Vento S, Vergara M, Gauthier B, Trachtman H . Efficacy of mycophenolate mofetil in paediatric patients with steroid-dependent nephrotic syndrome. Pediatr Nephrol 2005; 20: 1265–1268.
Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data: results of the First International Workshop. Am J Ophthalmol 2005; 140: 509–516.
Nussenblatt RB, Palestine AG, Chan CC, Roberge F . Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology 1985; 92: 467–471.
Thorne JE, Jabs DA, Qazi FA, Nguyen OD, Kempen JH, Dunn JP . Mycophenolate mofetil therapy for inflammatory eye disease. Ophthalmology 2005; 112: 1472–1477.
Siepmann K, Huber M, Stübiger N, Deuter C, Zierhut M . Mycophenolate mofetil is a highly effective and safe immunosuppressive agent for the treatment of uveitis: a retrospective analysis of 106 patients. Graefes Arch Clin Exp Ophthalmol 2006; 244: 788–794.
Sobrin L, Christen W, Foster CS . Mycophenolate mofetil after methotrexate failure or intolerance in the treatment of scleritis and uveitis. Ophthalmology 2008; 115: 1416–1421.
Baltatzis S, Tufail F, Yu EN, Vredeveld CM, Foster CS . Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders. Ophthalmology 2003; 110: 1061–1065.
Teoh SC, Hogan AC, Dick AD, Lee RW . Mycophenolate mofetil for the treatment of uveitis. Am J Ophthalmol 2008; 146: 752–760.
Daniel E, Thorne JE, Newcomb CW, Pujari SS, Kaçmaz RO, Levy-Clarke GA et al. Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol 2010; 149: 423–432.e1-2.
Doycheva D, Deuter C, Stuebiger N, Biester S, Zierhut M . Mycophenolate mofetil in the treatment of uveitis in children. Br J Ophthalmol 2007; 91: 180–184.
Okada AA . Immunomodulatory therapy for ocular inflammatory disease: a basic manual and review of the literature. Ocul Immunol Inflamm 2005; 13: 335–351.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
This study was presented as a poster at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in May 2009.
Rights and permissions
About this article
Cite this article
Chang, P., Giuliari, G., Shaikh, M. et al. Mycophenolate mofetil monotherapy in the management of paediatric uveitis. Eye 25, 427–435 (2011). https://doi.org/10.1038/eye.2011.23
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/eye.2011.23
Keywords
This article is cited by
-
Juvenile Uveitis
Spektrum der Augenheilkunde (2024)
-
An Update on Treatment of Pediatric Chronic Non-infectious Uveitis
Current Treatment Options in Rheumatology (2017)
-
Morphological assessment of the retina in uveitis
Journal of Ophthalmic Inflammation and Infection (2016)
-
Medication use in juvenile uveitis patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance Registry
Pediatric Rheumatology (2016)
-
Juvenile idiopathic arthritis-associated uveitis
Pediatric Rheumatology (2016)
